Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.
Chapman JW, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA, Virk S, Goss PE, Ingle JN, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Gelmon KA, Whelan TJ, Elliott C, Shepherd LE, Chen BE, Taylor KJ. Chapman JW, et al. Among authors: taylor kj. J Clin Oncol. 2024 Aug 20;42(24):2887-2898. doi: 10.1200/JCO.24.00835. Epub 2024 Jun 2. J Clin Oncol. 2024. PMID: 38824432 Clinical Trial.
Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga RC, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Bartlett JMS, et al. Among authors: taylor kj. Clin Cancer Res. 2022 May 2;28(9):1871-1880. doi: 10.1158/1078-0432.CCR-21-3385. Clin Cancer Res. 2022. PMID: 35144966 Free PMC article. Clinical Trial.
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel E, Pirrie S, Schnabel CA, Rea D, Bartlett JMS. Sgroi DC, et al. Among authors: taylor kj. Breast Cancer Res. 2022 Dec 16;24(1):90. doi: 10.1186/s13058-022-01589-x. Breast Cancer Res. 2022. PMID: 36527133 Free PMC article.
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.
Bartlett JMS, Xu K, Wong J, Pond G, Zhang Y, Spears M, Salunga R, Mallon E, Taylor KJ, Hasenburg A, Markopoulos C, Dirix L, van de Velde CJH, Rea D, Schnabel CA, Treuner K, Bayani J. Bartlett JMS, et al. Among authors: taylor kj. Clin Cancer Res. 2024 Apr 15;30(8):1509-1517. doi: 10.1158/1078-0432.CCR-23-2436. Clin Cancer Res. 2024. PMID: 38345755 Free PMC article.
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
Williams LJ, Kunkler IH, Taylor KJ, Dunlop J, Piper T, Caldwell J, Jack W, Loane JF, Elder K, Bartlett JMS, Dixon JM, Cameron DA. Williams LJ, et al. Among authors: taylor kj. Lancet Oncol. 2024 Sep;25(9):1213-1221. doi: 10.1016/S1470-2045(24)00347-4. Epub 2024 Aug 7. Lancet Oncol. 2024. PMID: 39127062 Clinical Trial.
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
Karlsson P, Fyles A, Chang SL, Arrick B, Baehner FL, Malmström P, Fernö M, Holmberg E, Sjöström M, Liu FF, Cameron DA, Williams LJ, Bartlett JMS, Dunlop J, Caldwell J, Loane JF, Mallon E, Piper T, Kunkler I, Feng FY, Speers CW, Pierce LJ, Bennett JP, Taylor KJ. Karlsson P, et al. Among authors: taylor kj. J Natl Cancer Inst. 2025 Mar 1;117(3):486-495. doi: 10.1093/jnci/djae262. J Natl Cancer Inst. 2025. PMID: 39423142 Free PMC article.
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.
Chapman JW, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA, Virk S, Goss PE, Ingle JN, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Gelmon KA, Whelan TJ, Elliott C, Shepherd LE, Chen BE, Taylor KJ. Chapman JW, et al. Among authors: taylor kj. Breast Cancer Res Treat. 2025 Jun 23. doi: 10.1007/s10549-025-07749-9. Online ahead of print. Breast Cancer Res Treat. 2025. PMID: 40549110
321 results